Total Payments
$6,430
2024 Payments
$1,316
Companies
65
Transactions
316
Medicare Patients
5,243
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$5,791 (90.1%)
Education$639.37 (9.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,791 | 300 | 90.1% |
| Education | $639.37 | 16 | 9.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $723.83 | 41 | $0 (2024) |
| PFIZER INC. | $408.46 | 25 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $374.88 | 21 | $0 (2024) |
| Celgene Corporation | $329.31 | 13 | $0 (2024) |
| Genentech USA, Inc. | $321.91 | 18 | $0 (2024) |
| Amgen Inc. | $306.85 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $256.79 | 16 | $0 (2024) |
| SHIELD THERAPEUTICS INC | $214.66 | 5 | $0 (2024) |
| GENZYME CORPORATION | $210.87 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $202.29 | 10 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,316 | 58 | SHIELD THERAPEUTICS INC ($214.66) |
| 2023 | $986.17 | 48 | E.R. Squibb & Sons, L.L.C. ($109.10) |
| 2022 | $626.34 | 32 | Novartis Pharmaceuticals Corporation ($143.18) |
| 2021 | $404.75 | 16 | Servier Pharmaceuticals LLC ($159.26) |
| 2020 | $573.01 | 16 | Amgen Inc. ($190.00) |
| 2019 | $644.71 | 34 | Celgene Corporation ($139.84) |
| 2018 | $1,210 | 73 | E.R. Squibb & Sons, L.L.C. ($196.30) |
| 2017 | $668.67 | 39 | E.R. Squibb & Sons, L.L.C. ($186.66) |
All Payment Transactions
316 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $54.36 | General |
| Category: Hematology | ||||||
| 12/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.52 | General |
| 12/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $82.58 | General |
| Category: Hematology | ||||||
| 11/25/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Hematology | ||||||
| 11/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Cardiovascular | ||||||
| 10/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.11 | General |
| Category: Hematology | ||||||
| 09/26/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: HORMONE THERAPY | ||||||
| 09/25/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $21.98 | General |
| 09/23/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $5.02 | General |
| Category: Oncology | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $32.38 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Oncology | ||||||
| 09/03/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $38.38 | General |
| Category: Hematology | ||||||
| 08/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Oncology | ||||||
| 08/12/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Hematology | ||||||
| 07/18/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,473 | 76,460 | $4.2M | $1.1M |
| 2022 | 26 | 1,381 | 66,691 | $1.7M | $392,668 |
| 2021 | 24 | 1,310 | 52,046 | $1.3M | $264,325 |
| 2020 | 25 | 1,079 | 40,385 | $1.1M | $222,477 |
Total Patients
5,243
Total Services
235,582
Medicare Billing
$2.0M
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 14,000 | $2.1M | $606,512 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 8,640 | $608,640 | $160,217 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 208 | 850 | $255,850 | $122,095 | 47.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 24 | 3,000 | $226,000 | $50,089 | 22.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 19 | 15,630 | $328,230 | $36,783 | 11.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 52 | 324 | $222,264 | $36,212 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 264 | $59,136 | $27,541 | 46.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 54 | 178 | $54,112 | $9,655 | 17.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 238 | 1,073 | $32,190 | $8,166 | 25.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 115 | $23,575 | $7,109 | 30.2% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 13 | 25,920 | $51,840 | $6,708 | 12.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 21 | 118 | $39,412 | $6,564 | 16.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 56 | 254 | $38,608 | $6,193 | 16.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 221 | 696 | $13,224 | $5,846 | 44.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $9,072 | $3,806 | 42.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 72 | 327 | $30,411 | $3,772 | 12.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 90 | $14,040 | $2,180 | 15.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 110 | $11,550 | $1,460 | 12.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 17 | 17 | $3,098 | $1,283 | 41.4% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 24 | 86 | $6,278 | $941.00 | 15.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 23 | 870 | $106,140 | $702.94 | 0.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 20 | $1,380 | $539.40 | 39.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 16 | 16 | $896.00 | $512.80 | 57.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 67 | 3,463 | $3,463 | $338.48 | 9.8% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 38 | 147 | $2,793 | $168.16 | 6.0% |
About Dr. John Sprandio, M.D
Dr. John Sprandio, M.D is a Hematology & Oncology healthcare provider based in Broomall, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144268913.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Sprandio, M.D has received a total of $6,430 in payments from pharmaceutical and medical device companies, with $1,316 received in 2024. These payments were reported across 316 transactions from 65 companies. The most common payment nature is "Food and Beverage" ($5,791).
As a Medicare-enrolled provider, Sprandio has provided services to 5,243 Medicare beneficiaries, totaling 235,582 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Broomall, PA
- Active Since 06/03/2006
- Last Updated 02/06/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144268913
Products in Payments
- OPDIVO (Biological) $487.90
- KEYTRUDA (Biological) $231.00
- ACCRUFER (Drug) $214.66
- XTANDI (Drug) $185.57
- ELIQUIS (Drug) $162.34
- TIBSOVO (Drug) $159.26
- TAGRISSO (Drug) $145.62
- Stivarga (Drug) $136.69
- Lenvima (Drug) $134.90
- ADCETRIS (Biological) $133.81
- Abraxane (Drug) $132.21
- SARCLISA (Biological) $118.03
- Imbruvica (Drug) $107.58
- PADCEV (Biological) $102.19
- JAKAFI (Drug) $88.64
- IBRANCE (Drug) $84.91
- MONJUVI (Drug) $84.28
- Enhertu (Drug) $83.98
- CALQUENCE (Drug) $80.57
- FOTIVDA (Drug) $70.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.